지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2007.12
- 수록면
- 454 - 458 (5page)
이용수
초록· 키워드
오류제보하기
Purpose: Basiliximab has become widely used in clinical practice for initial immunosuppression in renal transplantation cases, to reduce the incidence of acute rejection without adverse events. Herein, we report the early outcomes of renal transplantation using basiliximab at a single center.
Methods: This retrospective study included 148 renal allograft recipients at a single center. All patients were followed for longer than 1 year after transplantation, and treated with a calcineurin inhibitor and steroids for maintenance immunosuppression. The use of basiliximab and mycophenolate mofetil (MMF) was optional. We compared the incidence of episodes of acute graft rejection in kidney recipients who were treated with basiliximab as an initial immunosuppressive therapy with those who were treated without basiliximab.
Results: Basiliximab was used for initial immunosuppression in 58 patients. Patients maintained immunosuppression with triple (n=69) or double (n=79) regimens including a calcineurin inhibitor (cyclosporine A (n=111) or tacrolimus (n=37)) and methylprednisolone with or without MMF. Thirty-six (24.3%) patients had a rejection episode within 1 year after transplantation and twenty-six (17.6%) patients had an episode of infection. The patients who were treated with basiliximab had fewer rejection episodes (n=11, 18.9%) within the first year after transplantation than the patients who did not take basiliximab (n=25, 27.7%); this difference was not statistically significant. (P=0.245). However, basiliximab significantly affected the number of rejection episodes in the double regi men group (P=0.006), but not the number of rejections in the triple regimen group (P=0.432) and did not affect the number of infection episodes in both groups (P value of double, triple=0.291, 0.772) within one year after transplantation.
Conclusion: The results of this study suggest that basiliximab might be more useful for graft recipients who are treated with double immunosuppression with a calcineurin inhibitor and steroid than for the recipients with triple immunosuppression including MMF.
Methods: This retrospective study included 148 renal allograft recipients at a single center. All patients were followed for longer than 1 year after transplantation, and treated with a calcineurin inhibitor and steroids for maintenance immunosuppression. The use of basiliximab and mycophenolate mofetil (MMF) was optional. We compared the incidence of episodes of acute graft rejection in kidney recipients who were treated with basiliximab as an initial immunosuppressive therapy with those who were treated without basiliximab.
Results: Basiliximab was used for initial immunosuppression in 58 patients. Patients maintained immunosuppression with triple (n=69) or double (n=79) regimens including a calcineurin inhibitor (cyclosporine A (n=111) or tacrolimus (n=37)) and methylprednisolone with or without MMF. Thirty-six (24.3%) patients had a rejection episode within 1 year after transplantation and twenty-six (17.6%) patients had an episode of infection. The patients who were treated with basiliximab had fewer rejection episodes (n=11, 18.9%) within the first year after transplantation than the patients who did not take basiliximab (n=25, 27.7%); this difference was not statistically significant. (P=0.245). However, basiliximab significantly affected the number of rejection episodes in the double regi men group (P=0.006), but not the number of rejections in the triple regimen group (P=0.432) and did not affect the number of infection episodes in both groups (P value of double, triple=0.291, 0.772) within one year after transplantation.
Conclusion: The results of this study suggest that basiliximab might be more useful for graft recipients who are treated with double immunosuppression with a calcineurin inhibitor and steroid than for the recipients with triple immunosuppression including MMF.
목차
서론
방법
결과
고찰
REFERENCES
참고문헌 (14)
참고문헌 신청
1. [학술지(정기간행물)] - Ponticelli C / 2004 / From cyclosporine to the future / Transplant Proc 36 : 557 ~ 560
2. [학술지(정기간행물)] - Almond PS / 1993 / Risk factors for chronic rejection in renal allograft recipients / Transplantation 55 : 752 ~ 757
3. [학술지(정기간행물)] - Bone JM / 2005 / Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy / Transplantation 79 : 119 ~ 122
4. [학술지(정기간행물)] - Vanrenterghem Y / 1999 / Strategies to reduce or replace steroid dosing / Transplant Proc 31 : 7 ~ 10
5. [학술지(정기간행물)] - Chang GJ / 2000 / A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function / Clin Transplant 14 : 550 ~ 554
2. [학술지(정기간행물)] - Almond PS / 1993 / Risk factors for chronic rejection in renal allograft recipients / Transplantation 55 : 752 ~ 757
3. [학술지(정기간행물)] - Bone JM / 2005 / Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy / Transplantation 79 : 119 ~ 122
4. [학술지(정기간행물)] - Vanrenterghem Y / 1999 / Strategies to reduce or replace steroid dosing / Transplant Proc 31 : 7 ~ 10
5. [학술지(정기간행물)] - Chang GJ / 2000 / A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function / Clin Transplant 14 : 550 ~ 554
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
간이식 환자의 Basiliximab 유도요법에 대한 임상적 고찰
대한외과학회 학술대회 초록집
2004 .05
-
Comparison of outcome between low dose rabbit Antithymocyte Globulin and Basiliximab in Low -risk Living Donor Kidney transplantation
대한외과학회 학술대회 초록집
2019 .10
-
안면이식에 대한 최근 동향: 한국에서의 안면이식은 어떤 단계에 있는가?
Archives of craniofacial surgery : ACFS
2012 .01
-
신장이식 200예의 술후 합병증에 관한 임상적 분석
Annals of Surgical Treatment and Research
1993 .12
-
신장이식에서 Anti IL2 Receptor Monoclinal Ab (Basiliximab, Simulect)의 사용 경험
대한외과학회 학술대회 초록집
2003 .05
-
신장이식
보험의학회지
1999 .01
-
Rituximab, Plasma Exchange, Basiliximab, and IVIG without Local Infusion and Splenectomy : a Case Report in ABO Incompatible Living Donor Liver Transplantation
한국간담췌외과학회 학술대회지
2012 .04
-
Towards Steroid-Free Immunosuppression after Liver Transplantation
Gut and Liver
2016 .01
-
생체 신이식후 발생한 급성거부반응의 스테로이드 대량요법에 대한 반응
Annals of Surgical Treatment and Research
1993 .12
-
신장이식에서의 가속성 급성거부반응 발생과 이식 장기의 생존에 관련된 요인에 관한 고찰
Annals of Surgical Treatment and Research
1997 .01
-
신이식 후 면역반응의 이해 2부 이식면역검사와 면역억제제
Childhood Kidney Diseases
2008 .01
-
신장이식 200예의 임상 분석
Annals of Surgical Treatment and Research
1991 .08
-
신장이식 100예의 임상적 고찰
Annals of Surgical Treatment and Research
1985 .07
-
A new simplified protocol using Rituximab, Plasma exchange, Basiliximab, and IVIG without graft local infusion and splenectomy for ABO incompatible living donor liver transplantation
한국간담췌외과학회 학술대회지
2013 .04
-
신이식환자에서 이식과 환자의 생존에 영향을 끼치는 위험요인 분석
한국임상약학회지
2006 .01
-
신장이식 후 발생한 합병증
Annals of Surgical Treatment and Research
2002 .10
-
신장이식
대한내과학회지
2014 .01
-
Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients in Korea
Yonsei Medical Journal
2009 .01
-
신장이식후 사용중인 면역억제요법의 변경사유 및 변경후 예후에 관한 연구
Annals of Surgical Treatment and Research
1990 .05
이 논문의 저자 정보
이 논문과 함께 이용한 논문
생체신장이식과 사체신장이식에서의 이식신 및 환자 생존율에 관한 예후인자
박제훈
,
우돈희
,
이광웅
외 4명
대한외과학회 학술대회 초록집
2002
.10
신장이식 500예의 임상적 고찰
김주성
,
김형태
,
조원현
외 4명
대한외과학회 학술대회 초록집
2001
.05
신장 공여자의 나이에 따른 생체 신장이식의 결과
김순일
,
김명수
,
문장일
외 2명
대한외과학회 학술대회 초록집
2000
.05
신장이식 후 당뇨병 발생의 위험인자 분석
안형준
,
김명수
,
김현정
외 5명
대한외과학회 학술대회 초록집
2005
.10
신장이식 환자에서의 BK 바이러스 감염의 임상적 의의
박관태
,
김송철
,
한덕종
외 2명
대한외과학회 학술대회 초록집
2007
.05
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-514-002682853